Jazz Pharmaceuticals (JAZZ) Stock Price Target 2026

The average analyst price target for Jazz Pharmaceuticals is $266.44, 9.6% above the current price. Of 20 analysts, 18 rate it Buy and 2 Hold. Targets range from $150 to $337. The latest change came on Nov 3, 2026, when JP Morgan raised its price target on Jazz Pharmaceuticals from $300 to $310 and kept an Overweight rating.

The Average Analyst Price Target for Jazz Pharmaceuticals is $266.44.

Price Target Range — 9 Quarters

Analyst Consensus — 20 Analysts

18Buy

2Hold

Consensus RatingBuy# Analysts20Avg. Consensus PT$266.44Upside to Avg. PT+9.6%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Jazz Pharmaceuticals Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 3, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$300→$310
Nov 3, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$314→$319
Nov 3, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$296→$305
Nov 3, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$271→$275
Oct 28, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$276→$300
Oct 21, 2026	Morgan Stanley	Jeffrey Hung	PT Cut	Overweight	$322→$314
Oct 8, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$299→$296
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$281→$286
Sep 30, 2026	Citigroup	Geoff Meacham	Initiate	Buy	$325
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$337
Sep 11, 2026	UBS	Ashwani Verma	PT Raise	Buy	$315→$337
Sep 10, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$270→$271
Aug 26, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$287→$300
Aug 26, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$283→$322
Aug 26, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$264→$281
Aug 26, 2026	Needham	Ami Fadia	PT Raise	Buy	$292→$310
Aug 11, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$280→$283
Aug 4, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$265→$276
Aug 4, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$254→$264
Aug 4, 2026	TD Cowen	Joseph Thome	PT Raise	Buy	$275→$300

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $300 to $310.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $319

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $314 to $319.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $305

RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $296 to $305.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $275

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $271 to $275.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $276 to $300.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $314

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target from $322 to $314.

Benzinga Newsdesk

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals (JAZZ) Stock Price Target 2026

The Average Analyst Price Target for Jazz Pharmaceuticals is $266.44.

Latest Upgrades and Downgrades for Jazz Pharmaceuticals Stock

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $319

PRO
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $305

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $275

PRO
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $314

People Also Watch

People Also Watch

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals (JAZZ) Stock Price Target 2026

The Average Analyst Price Target for Jazz Pharmaceuticals is $266.44.

Latest Upgrades and Downgrades for Jazz Pharmaceuticals Stock

Analyst Ratings News

PROJP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310

PROMorgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $319

PRORBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $305

PROBarclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $275

PROJP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300

PROMorgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $314

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $319

PRO
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $305

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $275

PRO
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $314